---
id: interferons-mechanism_265
category: antimicrobials
tags: [antivirals, interferons, peginterferon, innate-immunity, JAK-STAT]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Interferons: Mechanism and Clinical Applications

**Q:** What is the mechanism of action of interferons, and what are the clinical indications for peginterferon? (Use mnemonic **JAK-ISG**)

**A:**

**Mechanism (JAK-ISG Pathway):**
1. IFN binds type 1 IFN receptor → receptor dimerization
2. **J**anus kinase (**JAK**) → **STAT** pathway activation
3. ↑ Expression of **I**FN-**S**timulated **G**enes (**ISG**)
4. **Antiviral effector proteins** produced → non-specific antiviral state

**Immune Effects:**
- **Innate:** NK cell activation, dendritic cell maturation
- **Adaptive:** Memory T-cell proliferation, prevent T-cell apoptosis
- Result: ↓ viral replication, protect uninfected cells

**Clinical Applications:**
- **Peginterferon alfa-2a/2b** (PEGylated = prolonged half-life)
- **Hepatitis B** (chronic): Peginterferon therapy (finite duration)
- **Hepatitis C** (historical): Peginterferon + ribavirin (now replaced by DAAs)
- **IFN-λ (lambda)**: Type III IFN, fewer systemic effects

**Key Limitation:** Non-specific immune activation → flu-like symptoms, depression, cytopenias

**Pearl:** DAAs have largely replaced interferons for HCV due to better tolerability and efficacy.

**Media:**

**Sources:** [DrugBank Peginterferon alfa-2a], [PMC4757589 - Peginterferon Pathway], [NCBI Bookshelf Alpha Interferon NBK547867], [Frontiers Interferon & Hepatitis B 2021]
